You searched for Athersys - Page 3 of 4

COVID-19 cellular medicine buzz: Mesoblast, FTC hammer, more

April 26, 2020 / Professor Paul Knoepfler, Ph.D. / 3 Comments

It’s been a busy week for the cellular and regenerative medicine space for COVID-19 news with some possible ups including for Mesoblast and some definite downs. Starting with the more positive media buzz with have Mesoblast. Mesoblast made COVID19 news “Thinly traded Mesoblast Limited (NASDAQ:MESO) rockets 51% premarket on average volume in reaction to its announcement of an […]

COVID-19 cellular medicine buzz: Mesoblast, FTC hammer, more Read More »

Cell therapy trials for COVID-19 accelerate & some early reports

April 13, 2020 / Professor Paul Knoepfler, Ph.D. / 11 Comments

MultiStem-Athersys-cell-therapy-COVID-19

Could various kinds of cell therapy help patients with COVID-19? A variety of cell therapies, mostly focused on mesenchymal stromal/stem cells (MSCs), have gotten cleared quickly in the U.S., China, and Israel and possibly other countries to be tested in patients with the novel coronavirus. I hope at least one proves helpful. It’s mostly a

Cell therapy trials for COVID-19 accelerate & some early reports Read More »

The Niche COVID-19 updates & resources

March 10, 2020 / Professor Paul Knoepfler, Ph.D.

stem-cells-for-COVID-19-infographic_small

The novel coronavirus and the disease it causes, COVID-19, have swept the world with few proven treatment options. Vaccines are only recently being rolled out the last 2 or so months, which gives some real hope. While the novel coronavirus-caused illness is generally a mild disease in kids (many of whom don’t even show symptoms),

The Niche COVID-19 updates & resources Read More »

B+ on my report card on my 20 stem cell predictions for 2019

December 26, 2019 / Professor Paul Knoepfler, Ph.D. / 9 Comments

Last year around this time I took my annual plunge to make 20 predictions for the coming year for the stem cell and regenerative medicine field. I even made a crystal ball graphic to highlight the complexity of the stem cell ecosystem into which these predictions were embedded (see image) for 2019. How’d I do?

B+ on my report card on my 20 stem cell predictions for 2019 Read More »

FDA Regenerative Medicine Advanced Therapy RMAT designations jump to 36

September 24, 2019 / Professor Paul Knoepfler, Ph.D. / 2 Comments

Peter-Marks-Regenerative-Medicine-Advanced-Therapy-Designation-RMAT-

This post includes my updated list of firms/products that have received FDA regenerative medicine advanced therapy designation or RMAT, which are in the public domain. The numbers really jumped in the last month. I’m assuming for the purposes of this resource page that all self-reports are accurate. Note that the links embedded into the firm

FDA Regenerative Medicine Advanced Therapy RMAT designations jump to 36 Read More »

20 stem cell & regenerative medicine predictions for 2019

January 2, 2019 / Professor Paul Knoepfler, Ph.D. / 6 Comments

For a long time at the end of each year, I’ve been making stem cell predictions for the coming year. Most often I’ve been making a “top 20” list of predictions and today’s post has my list for 2019. You can see how I did for 2018 here, which might have been my best year

20 stem cell & regenerative medicine predictions for 2019 Read More »

Updated FDA granted RMAT List (85)

January 10, 2018 / Professor Paul Knoepfler, Ph.D.

Today’s post includes a list of firms/products that have self-reported that they have received FDA regenerative medicine advanced therapy designation or RMAT. Sometimes people call these “r mat” with a space. As of December 12, 2023 there are 85 RMATs in the public domain. I also include FDA data on RMAT submissions via an FDA RMAT resource

Updated FDA granted RMAT List (85) Read More »

Mesoblast gets FDA RMAT; List of 10 total designations so far

December 26, 2017 / Professor Paul Knoepfler, Ph.D. / 13 Comments

Australian stem cell biotech Mesoblast announced that it has received regenerative medicine advanced therapy (RMAT) designation from the U.S. FDA. This is very good news for the company and an encouraging development for the field. Interestingly, last month the FDA clarified that there is expanded RMAT designation that can include gene therapies too. At the Meeting

Mesoblast gets FDA RMAT; List of 10 total designations so far Read More »

Grading my twenty 2017 stem cell predictions

December 20, 2017 / Professor Paul Knoepfler, Ph.D. / 3 Comments

Each year I make a list of predictions for the year to come for the stem cell and regenerative medicine field. Then about a year later I grade myself on how I did as that year winds down. Here’s how I did in 2016. For 2017, late in 2016 I made 20 stem cell predictions. Let’s

Grading my twenty 2017 stem cell predictions Read More »

2017 stem cell predictions: score card at 1/2-way point

June 18, 2017 / Professor Paul Knoepfler, Ph.D. / 1 Comment

In December of each year I make a list of stem cell predictions for the coming year, and I made 20 such predictions for 2017 so I’m wondering how I’m doing so far on these now that it’s June. Below is my work-in-progress scorecard for these so far. Positive news from Asterias on trial for stem cell-based

2017 stem cell predictions: score card at 1/2-way point Read More »

Search Results for: Athersys